Pfizer RSV Shot Meets Goals in Trial Of High-risk Adults Under Age 60 Pfizer RSV Shot Meets Goals in Trial Of High-risk Adults Under Age 60

Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60...Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news